Printer Friendly

Genzyme unveils AUBAGIO 14 mg as a first-line once daily oral tablet for treating relapsing remitting multiple sclerosis in Canada.

M2 EQUITYBITES-May 26, 2015-Genzyme unveils AUBAGIO 14 mg as a first-line once daily oral tablet for treating relapsing remitting multiple sclerosis in Canada

(C)2015 M2 COMMUNICATIONS http://www.m2.com

Genzyme announced on Monday the addition of AUBAGIO 14 mg on the provincial drug formulary as a first-line once daily oral tablet for treating people living with relapsing remitting multiple sclerosis (RRMS) in Canada through PEI Pharmacare.

The company said AUBAGIO (teriflunomide) is indicated as monotherapy for the treatment of RRMS to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability. MS is the most common neurological disease affecting young adults in Canada.

According to the company, MS One to One programme offers comprehensive information services and ongoing education, as well as reimbursement navigation. Staffed by dedicated MS nurses and highly trained representatives, MS One to One provides support for individuals living with MS, their healthcare providers, family and loved ones.

AUBAGIO (Teriflunomide) is an immunomodulator with anti-inflammatory properties and may involve a reduction in the number of activated lymphocytes in the central nervous system (CNS). AUBAGIO is supported by one of the largest clinical programmes of any MS therapy, with more than 5,000 trial participants in 36 countries. Some patients in extension trials have been treated for up to ten years and are still benefiting from the treatment, added the company.

Genzyme is engaged in the development of transformative therapies for patients affected by rare and debilitating diseases and is part of Sanofi (Euronext:SAN.NX) (NYSE:SNY).

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Geographic Code:1CANA
Date:May 26, 2015
Words:267
Previous Article:Pharming to distribute Ruconest through Cytobioteck for treating HAE in Colombia and Venezuela.
Next Article:Axis' board notifies dividend proposal receipt.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters